ReviewEndocrine2026
Homocysteine and mitophagy in diabetic retinopathy: unraveling the underlying molecular crosstalk.
Review in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeDiabetic retinopathy (DR), the leading cause of blindness among microvascular complications of diabetes, remains poorly understood regarding its pathogenesis, with effective clinical interventions remaining limited. Emerging evidence indicates that hyperhomocysteinemia (HHcy) and mitochondrial autophagy dysfunction act synergistically as key pathogenic drivers in DR progression, where their interactive cascade serves as a central mechanism disrupting retinal homeostasis.
methodsThis review systematically examines the complex mechanisms through which HHcy induces oxidative stress, inflammation, and endothelial dysfunction contributing to retinal injury, while elucidating the stage-specific regulatory dynamics of mitochondrial autophagy during DR pathogenesis.
resultsWe specifically investigate the molecular mechanism by which HHcy triggers mitochondrial autophagy dysfunction through oxidative stress-mediated regulation of the AMPK/mTOR signaling axis, thereby establishing a pathogenic positive feedback loop that accelerates DR progression.
conclusionsGiven the current lack of direct causal evidence, absence of retina-specific in vivo models, and incomplete understanding of their dynamic interactions, comprehensive analysis of core molecular nodes within the "HHcy-mitochondrial autophagy" regulatory axis is expected to refine the theoretical framework of DR pathogenesis while providing experimental foundations for developing targeted therapeutic strategies against DR-induced retinal damage.
Indexed as
Identifiers
42747637What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.